Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD-Reference-Cited by-同舟云学术

Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD

Published:2019-09 Issue:3 Volume:74 Page:328-337
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Allegretti Andrew S.,Zhang Wenbin,Zhou Wenjiong,Thurber Tara K.,Rigby Scott P.,Bowman-Stroud Cynthia,Trescoli Carlos,Serusclat Pierre,Freeman Mason W.,Halvorsen Yuan-Di C.

Funder

Massachusetts General Hospital

Publisher

Elsevier BV

Subject

Nephrology

Reference26 articles.

1. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Di Angelantonio;Lancet,2010

2. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018;Diabetes Care,2018

3. KDOQI clinical practice guideline for diabetes and CKD: 2012 update;Am J Kidney Dis,2012

4. Temporal trends in the prevalence of diabetic kidney disease in the United States;de Boer;JAMA,2011

5. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area;Coll-de-Tuero;BMC Nephrol,2012

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus;Medicinal Chemistry Research;2024-07-10

2. Bexagliflozin in type 2 diabetes: a profile of its use;Drugs & Therapy Perspectives;2024-07

3. Pharmacological Treatment of Diabetes Mellitus: An Overview of New Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetes Mellitus;Journal of Endocrinology and Metabolism;2024-06

4. Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics;Asian Journal of Pharmaceutical Sciences;2024-06

5. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21